Orchard Kim, Barrington Sally, Buscombe John, Hilson Andrew, Prentice Hugh Grant, Mehta Atul
Department of Haematology, Royal Free and University College Medical School, Royal Free Campus, Clinical PET Centre, Guys, Kings and St. Thomas's Hospitals, London, UK.
Br J Haematol. 2002 Apr;117(1):133-5. doi: 10.1046/j.1365-2141.2002.03407.x.
Positron emission tomography with 2-deoxy-2-[18]fluoro-D-glucose (FDG-PET) imaging has been extensively used to detect occult metastatic malignant lesions in patients with carcinoma. We describe its use in three patients with multiple myeloma, each representing a particular clinical situation in which this imaging modality offered advantages over plain radiography, computerized tomography or magnetic resonance imaging. FDG-PET provides a whole body image showing sites of occult disease. This is of particular value in patients with non-secretory myeloma, solitary plasmacytoma or for those that relapse with focal disease following autologous or allogeneic stem cell transplantation.
使用2-脱氧-2-[18]氟-D-葡萄糖正电子发射断层扫描(FDG-PET)成像已被广泛用于检测癌症患者隐匿性转移性恶性病变。我们描述了其在三名多发性骨髓瘤患者中的应用,每位患者均代表一种特殊的临床情况,在此种情况下,这种成像方式相对于普通X线摄影、计算机断层扫描或磁共振成像具有优势。FDG-PET可提供显示隐匿性疾病部位的全身图像。这在非分泌型骨髓瘤、孤立性浆细胞瘤患者或自体或异基因干细胞移植后局部疾病复发的患者中具有特殊价值。